CD43 Peptide Antigens for Specific AML Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches for acute myeloid leukemia (AML) lack suitable AML-specific antigens, hindering the development of effective immunizations and diagnostic tools, and existing antibodies are not specific enough to target AML cells without binding to non-malignant cells.
Innovation Solution
Development of isolated, recombinant or purified CD43 peptides with specific amino acid sequences that are identical to regions on the CD43 protein, which are used to elicit or detect a specific immune response against AML cells, utilizing antibody AT14-013 that binds specifically to AML cells while avoiding non-AML cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing antibodies are used to target AML cells, then some binding activity is achieved, but the antibodies lack specificity and bind to non-malignant cells as well
Solution Approach 1:
The patent segments the CD43 protein into specific peptide regions (amino acid positions 133-184) that are uniquely expressed on AML cells. By focusing on this specific segment rather than the entire CD43 protein, the antibody AT14-013 achieves high specificity for AML cells while avoiding binding to non-malignant cells that express CD43.
Solution Approach 2:
The invention applies local quality by identifying that the CD43 peptide at positions 133-184 has unique characteristics compared to other regions of CD43. This local region serves as the specific epitope that the antibody recognizes, providing localized specificity rather than broad binding across the entire protein.
2Measurement precision
If immunotherapy approaches are developed without AML-specific antigens, then general immune activation may occur, but effective and specific immune response against AML cannot be achieved
Solution Approach 1:
The patent extracts the specific CD43 peptide sequence (amino acid positions 133-184) from the full CD43 protein to create a defined immunogen. This extracted peptide serves as the specific antigen for immunotherapy, enabling the development of vaccines and diagnostic tools that target only AML cells expressing this specific peptide sequence.
3Object-affected harmful factors
If allogeneic stem cell transplantation is performed with T cell depletion to prevent GvHD, then graft versus host disease is reduced, but graft versus leukemia response is compromised leading to higher relapse rates
Solution Approach 1:
The patent uses the CD43 peptide (amino acid positions 133-184) as an intermediary target that can be recognized by antibodies and immune cells. This specific peptide serves as a mediator that enables selective targeting of AML cells through passive immunization or active immunization approaches, providing anti-leukemic activity without requiring T cell depletion that would compromise GvL response.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CD43 peptides effectively induce and detect a specific immune response against AML cells, providing a novel AML-specific antigen for immunotherapy and diagnostics, with antibody AT14-013 demonstrating binding specificity to AML cells without reacting with non-malignant CD43+ cells.
Implementation Method 1
antibody AT14-013 that binds specifically to AML cells while avoiding non-AML cells
Data Source
AI summary
The present invention provides novel compounds comprising an antigen of AML cells, and uses thereof.